BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama
Bergen, Norway, October 16, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan.BGB324, a first-in-class selective Axl inhibitor, is being investigated in three Phase 2 clinical trials across the three standard-of-care treatment regimens available to patients with non-small-cell lung cancer (NSCLC): these trials seek to
